Trans epidermal water loss inhibitor

Abstract

To provide a novel trans epidermal water loss inhibitor and a moisturizing agent using the inhibitor.SOLUTION: The characteristics of the present invention in order to solve the problem are as follows. 1. A trans epidermal water loss inhibitor has a kudzu vine-derived lactic acid bacterium (Leuconostoc mesenteroides) as an active ingredient. 2. The trans epidermal water loss inhibitor described in 1 above in which the kudzu vine-derived lactic acid bacterium (Leuconostoc mesenteroides) is a lactic acid bacterium (Leuconostoc mesenteroides) (Patent Organisms Depositary accession number: NITE P-02751) strain and / or a variant thereof. 3. A skin roughness improver has the trans epidermal water loss inhibitor described in 1 or 2 above as an active ingredient. 4. A moisturizing agent has the trans epidermal water loss inhibitor described in 1 or 2 above as an active ingredient. 5. A horny layer moisturizing and barrier protein (involucrin, filaggrin, transglutaminase 1) expression promoter has a kudzu vine-derived lactic acid bacterium (Leuconostoc mesenteroides)(Patent Organisms Depositary accession number: NITE P-02751) strain and / or a variant thereof as an active ingredient.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to an agent for suppressing transepidermal water loss. The present invention is widely used in food and drink products, pharmaceuticals, quasi-drugs, supplements, cosmetics, and the like.

Background Art

[0002] Maintaining and improving the skin condition is a matter of concern for both men and women regardless of age or era. Transepidermal water loss, also abbreviated as TEWL, is used for evaluating the skin barrier. Suppressing TEWL is evaluated as having a high barrier.

[0003] In order to enhance the skin barrier, Patent Document 1 proposes a topical skin preparation containing an extract of a plant of the genus Prunus of the Rosaceae family in order to further enhance the TEWL inhibitory effect of an organically modified clay mineral. Patent Document 2 proposes an oil-in-water type emulsion composition that suppresses TEWL and contains a propylene polymer having a weight average molecular weight of 25,000 to 100,000 and a melting point of 60°C to 100°C, a hydrocarbon oil having a melting point of less than 60°C, and an ester oil in a paste form at 25°C, with the total oil content being 5 to 20% by mass and the content ratio of the paste-like ester oil to the total oil content being 10 to 50% by mass (Patent Document 3).

[0004] Ulcerative colitis and Crohn's disease are still refractory inflammatory bowel diseases (IBD) with unclear etiologies. Factors related to inflammatory bowel disease include abnormalities in the intestinal flora, impaired production of secretory IgA by intestinal epithelial cells, and factors such as cytokines in the intestinal submucosa (Patent Document 4). In addition, Lactobacillus casei strain GG is known to have the potential to increase the IgA immune response in the intestine, thereby enhancing the intestinal immunological barrier. It has also been reported that intranasal administration of Lactobacillus rhamnosus GG protects mice from influenza virus infection by enhancing the cell-mediated immune response in the respiratory tract. Thus, IgA is known to have a function of defending against influenza infection and the like, and also has a function of defending foreign substances of viruses in the oral cavity (Patent Document 4).

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Disclosure of the Invention

Problems to be Solved by the Invention

[0006] Under such circumstances, the present inventors have found that lactic acid bacteria derived from the vine of kudzu have an action of suppressing the transdermal water evaporation amount and an action of promoting the expression of proteins for improving skin barrier function (involucrin, filaggrin expression amount transglutaminase 1), and have completed the present invention. In addition, through clinical trials, the present inventors have found that it has an action of suppressing the transdermal water evaporation amount, improving the collagen density, and increasing IgA, and have completed the present invention. That is, an object of the present invention is to provide a novel transdermal water evaporation amount inhibitor, a protein expression promoter for improving skin barrier function, an IgA increasing agent, a collagen density improving agent, and a barrier improving agent using these.

Means for Solving the Problems

[0007] The features of the present invention for solving the above problems are as follows. 1. A percutaneous water loss inhibitor containing lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vine as an active ingredient. 2. The percutaneous water loss inhibitor according to 1 above, wherein the lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vine is the strain of lactic acid bacteria (Leuconostoc mesenteroides) (Deposit number at the Patent Microorganisms Depositary: NITE P-02751) and / or its mutant strain. 3. A skin roughness improver containing the percutaneous water loss inhibitor according to 1 or 2 above as an active ingredient. 4. A moisturizer containing the percutaneous water loss inhibitor according to 1 or 2 above as an active ingredient. 5. An expression promoter of stratum corneum moisturizing and barrier proteins (involucrin, filaggrin, transglutaminase 1) containing lactic acid bacteria (Leuconostoc mesenteroides) (Deposit number at the Patent Microorganisms Depositary: NITE P-02751) derived from kudzu vine and / or its mutant strain as an active ingredient. 6. A dermal collagen density improver containing lactic acid bacteria (Leuconostoc mesenteroides) (Deposit number at the Patent Microorganisms Depositary: NITE P-02751) derived from kudzu vine and / or its mutant strain as an active ingredient. 7. A skin quality improver containing lactic acid bacteria (Leuconostoc mesenteroides) (Deposit number at the Patent Microorganisms Depositary: NITE P-02751) derived from kudzu vine and / or its mutant strain as an active ingredient. 8. An IgA increasing agent containing lactic acid bacteria (Leuconostoc mesenteroides) (Deposit number at the Patent Microorganisms Depositary: NITE P-02751) derived from kudzu vine and / or its mutant strain as an active ingredient.

Brief Description of the Drawings

[0008]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9A

Figure 9B

Figure 9C

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

Mode for Carrying Out the Invention

[0009] Hereinafter, the present invention will be described in detail. The present invention is characterized by containing lactic acid bacteria (Leuconostoc mesenteroides) derived from the vine of kudzu as an active ingredient.

[0010] Kuzu (Pueraria lobata) is a vine plant of the legume family, and its roots are widely used as raw materials for traditional Chinese medicines such as Gegen Decoction and as raw materials for kudzu starch known as Yoshino kudzu. In addition, the flowers of kudzu are used as raw materials for traditional Chinese medicines for the purpose of preventing hangovers, the vines are used as kudzu cloth and handicrafts, and the leaves have been widely used as livestock feed since ancient times. The lactic acid bacteria (Leuconostoc mesenteroides) derived from the vines of kudzu are not particularly limited as long as they are obtained from the vines of kudzu, but lactic acid bacteria (Leuconostoc mesenteroides), strains (Deposit number at the Patent Microorganisms Depositary Center: NITE P-02751) and its mutants are preferred. This is because it has an excellent effect of suppressing the percutaneous water evaporation amount.

[0011] The method for obtaining the strain of lactic acid bacteria (Deposit number at the Patent Microorganisms Depositary Center: NITE P-02751) is to accumulate and culture the vines of kudzu in a liquid medium for lactic acid bacteria added with antibiotics at 25°C to 37°C for 24 to 48 hours, smear and culture the obtained culture solution on a BCP-added plate count agar medium, and select 5 new vine strains (Deposit number at the Patent Microorganisms Depositary Center: NITE P-02751) belonging to Leuconostoc mesenteroides, whereby it can be obtained.

[0012] Typical culture conditions of the lactic acid bacteria 'Kuzunotsuru Lactic Acid Bacteria' (Leuconostoc mesenteroides) (Deposit number at the Patent Microorganisms Depositary Center: NITE P-02751) separated from the vines of kudzu (in this specification, the lactic acid bacteria with the deposit number NITE AP-02601 at the Patent Microorganisms Center are also referred to as 'Kuzunotsuru Lactic Acid Bacteria') are static culture in MRS medium at 25 to 37°C for 24 to 48 hours, but it is not limited thereto.

[0013] (Bacteriological characteristics) The novel 'Kuzunotsuru Lactic Acid Bacteria' (Deposit number NITE P-02751) belonging to Leuconostoc mesenteroides of the present invention has the following bacteriological characteristics characteristic of Leuconostoc mesenteroides and is used in fermented foods such as sauerkraut. This bacterium had the following bacteriological characteristics. · It is Gram-positive cocci in the form of chains or diplococci. · It is classified as hetero-lactic acid bacteria that decompose sugars to produce acetic acid, ethanol, CO 2 and other short-chain fatty acids other than lactic acid bacteria. (Definition of terms) The following lists the definitions of terms specifically used in this specification. The term "heated bacterial cells" used in this specification refers to bacterial cells that have been heat-sterilized after cultivation. Although not limited, typically, it refers to bacterial cells that have been cultivated at 20 to 40 °C for 10 to 40 hours and then heat-sterilized at 70 to 121 °C for 10 to 60 minutes.

[0014] Mutant strains of "Kuzunotsuru lactic acid bacteria" are prepared, for example, by performing general mutagenesis treatment or by adaptation through subculture or natural mutation. The mutagenesis treatment can be carried out using general mutagens. Examples of mutagens include agents having mutagenic effects, ultraviolet rays, etc. Examples of agents having mutagenic effects include streptomycin, ofloxacin, ethyl methanesulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, nucleotide base analogs such as bromouracil, or acridines, etc.

[0015] The percutaneous water transpiration amount inhibitor of the present invention can be used as a raw material for various foods and beverages. Examples of foods and beverages include general foods such as confectioneries (gums, candies, caramels, chocolates, cookies, snacks, jellies, gummies, tablet confections, etc.), noodles (buckwheat noodles, udon noodles, ramen noodles, etc.), dairy products (milk, ice cream, yogurt, etc.), seasonings (miso, soy sauce, etc.), soups, beverages (juices, coffee, black tea, tea, carbonated beverages, sports beverages, etc.), as well as health foods (tablets, capsules, etc.) and dietary supplements (nutritional drinks, etc.). It is advisable to appropriately blend the percutaneous water transpiration amount inhibitor of the present invention into these foods and beverages.

[0016] These food and beverage products can be formulated with various ingredients according to their types. For example, glucose, fructose, sucrose, maltose, sorbitol, stevioside, corn syrup, lactose, citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L - ascorbic acid, dl-α - tocopherol, sodium erythorbate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, gum arabic, carrageenan, casein, gelatin, pectin, agar, B vitamins, nicotinamide, calcium pantothenate, amino acids, calcium salts, pigments, flavors, and food materials of preservatives can be used.

[0017] As a specific manufacturing method, the percutaneous water loss inhibitor can be spray - dried or freeze - dried together with powdered cellulose, and then made into powder, granules, tablets or solutions, so that it can be easily incorporated into food and beverage products (such as instant foods). Also, the percutaneous water loss inhibitor can be dissolved in, for example, oils and fats, ethanol, glycerin or mixtures thereof to make it liquid, and then added to beverages or solid foods. If necessary, it can be mixed with binders such as gum arabic and dextrin to make it powdery or granular, and then added to beverages or solid foods.

[0018] When applying the percutaneous water loss inhibitor of the present invention to food and beverage products, the addition amount is preferably such that the total content of the active ingredient is 1 - 20 wt% or less with respect to the food and beverage products.

[0019] The transdermal water loss inhibitor of the present invention may be used as a material for drugs (including pharmaceuticals and quasi-drugs). The raw material for pharmaceutical preparations can be produced by appropriately blending the transdermal water loss inhibitor of the present invention. Examples of formulation raw materials that can be blended with the transdermal water loss inhibitor of the present invention include excipients (such as glucose, lactose, sucrose, sodium chloride, starch, calcium carbonate, kaolin, crystalline cellulose, cacao butter, hardened vegetable oil, kaolin, talc, etc.), binders (such as distilled water, physiological saline, ethanol water, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, potassium phosphate, polyvinylpyrrolidone, etc.), disintegrants (such as sodium alginate, agar, sodium hydrogen carbonate, calcium carbonate, sodium lauryl sulfate, monoglyceride stearate, starch, lactose, gum arabic powder, gelatin, ethanol, etc.), disintegration inhibitors (such as sucrose, stearin, cacao butter, hydrogenated oil, etc.), absorption promoters (such as quaternary ammonium base, sodium lauryl sulfate, etc.), adsorbents (such as glycerin, starch, lactose, kaolin, bentonite, silicic acid, etc.), lubricants (such as purified talc, stearate, polyethylene glycol, etc.).

[0020] The administration method of the transdermal water loss inhibitor of the present invention can generally be oral administration in the form of tablets, pills, soft and hard capsules, fine granules, powders, granules, liquids, etc., but parenteral administration may also be possible. When administered as a parenteral preparation, it can be administered into local tissues, intradermally, subcutaneously, intramuscularly, and intravenously in a solution state or in a state where a dispersant, suspending agent, stabilizer, etc. are added. It may also be in the form of suppositories. Furthermore, it can be administered as eye drops.

[0021] The dosage can vary depending on the administration method, disease condition, age of the patient, etc. In adults, usually 0.5 to 200 mg as the active ingredient per day, and in children, usually about 0.5 to 50 mg can be administered. The blending ratio of the percutaneous water loss inhibitor can be appropriately changed depending on the dosage form. Usually, when administered orally or by mucosal absorption, it is about 0.3 to 15.0 wt%, and when administered parenterally, it is preferably about 0.01 to 10 wt%. Note that the dosage varies depending on various conditions, so there may be cases where an amount less than the above dosage is sufficient, or there may be cases where it is necessary to administer beyond the range.

[0022] The percutaneous water loss inhibitor of the present invention can be expected to have a percutaneous water loss inhibitory effect even when used as a topical skin preparation (including cosmetics, pharmaceuticals, and quasi-drugs). Examples of the form of the topical skin preparation that can contain the percutaneous water loss inhibitor of the present invention include, for example, emulsions, soaps, facial washes, bath agents, creams, emulsions, lotions, colognes, beard shaving creams, beard shaving lotions, cosmetic oils, sunburn / sunblock lotions, face powders, foundations, perfumes, packs, nail creams, enamels, enamel removers, eyebrow pencils, blushes, eye creams, eye shadows, mascaras, eyeliners, lipsticks, lip creams, shampoos, rinses, hair dyes, dispersions, cleaning agents, etc. Examples of the form of the pharmaceutical or quasi-drug that can contain the percutaneous water loss inhibitor of the present invention include ointments, creams, topical solutions, etc.

[0023] In addition to the percutaneous water loss inhibitor according to the present invention, the above-mentioned topical skin preparations can contain components, oils, higher alcohols, fatty acids, ultraviolet absorbers, powders, pigments, surfactants, polyhydric alcohols / sugars, polymers, physiologically active components, solvents, antioxidants, fragrances, preservatives, etc. that are formulated in topical skin preparations such as cosmetics and quasi-drugs as long as the percutaneous water loss inhibitory effect is not impaired. Examples are listed below, but the present invention is not limited to these examples.

[0024] (1) Examples of oils Ester-based oil phase components: glyceryl tri(2-ethylhexanoate), cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, butyl stearate, butyl myristate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl myristate, isostearyl myristate, isostearyl palmitate, octyldodecyl myristate, isocetyl isostearate, diethyl sebacate, diisopropyl adipate, isoaralkyl neopentanoate, glyceryl tri(caprylic / capric acid), trimethylolpropane tri(2-ethylhexanoate), trimethylolpropane triisostearate, pentaerythritol tetra(2-ethylhexanoate), cetyl caprylate, decyl laurate, hexyl laurate, decyl myristate, myristyl myristate, cetyl myristate, stearyl stearate, decyl oleate, cetyl ricinoleate, isostearyl laurate, isotridecyl myristate, isocetyl myristate, isostearyl myristate, isocetyl palmitate, isostearyl palmitate, octyl stearate, isocetyl stearate, isodecyl oleate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, cetostearyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, propylene glycol di(caprylic / capric acid), propylene glycol dicaprylate, neopentyl glycol dicaprylate, neopentyl glycol dioctanoate, glyceryl tricaprylate, glyceryl triundecanoate, glyceryl triisopalmitate, glyceryl triisostearate, octyldodecyl neopentanoate, isostearyl octanoate, octyl isononanoate, hexyldecyl neodecanoate, octyldodecyl neodecanoate, isocetyl isostearate, isostearyl isostearate, octyldodecyl isostearate, polyglyceryl oleate, polyglyceryl isostearate, dipropyl carbonate,Dialkyl carbonates (C12-18), triisocetyl citrate, triisoalkyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, cetyl lactate, octyldecyl lactate, triethyl citrate, acetyltriethyl citrate, acetyltributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di-2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, dioctyl sebacate, cholesteryl stearate, cholesteryl isostearate, cholesteryl hydroxystearate, cholesteryl oleate, dihydrocholesteryl oleate, phytosteryl isostearate, phytosteryl oleate, isocetyl 12-stearoylhydroxystearate, stearyl 12-stearoylhydroxystearate, isostearyl 12-stearoylhydroxystearate, etc. Hydrocarbon-based oil phase components: squalane, liquid paraffin, α-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, petrolatum, etc. Animal and vegetable oils and their hydrogenated oils, and waxes of natural origin: animal oils such as beef tallow, hydrogenated beef tallow, lard, hydrogenated lard, horse oil, hydrogenated horse oil, mink oil, orange raffia oil, fish oil, hydrogenated fish oil, egg yolk oil and their hydrogenated oils, vegetable oils such as avocado oil, almond oil, olive oil, cocoa butter, kiwi seed oil, apricot kernel oil, kukui nut oil, sesame oil, wheat germ oil, rice germ oil, rice bran oil, safflower oil, shea butter, soybean oil, evening primrose oil, perilla oil, tea seed oil, camellia oil, corn oil, rapeseed oil, hydrogenated rapeseed oil, palm kernel oil, hydrogenated palm kernel oil, palm oil, hydrogenated palm oil, peanut oil, hydrogenated peanut oil, castor oil, hydrogenated castor oil, sunflower oil, grape seed oil, jojoba oil, hydrogenated jojoba oil, macadamia nut oil, meadowfoam oil, cottonseed oil, hydrogenated cottonseed oil, coconut oil, hydrogenated coconut oil and their hydrogenated oils, waxes such as beeswax, high acid value beeswax, lanolin, reduced lanolin, hydrogenated lanolin, liquid lanolin, carnauba wax, montan wax, etc. Silicone-based oil phase components: dimethylpolysiloxane, methylphenylpolysiloxane, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, methylhydrogenpolysiloxane, polyether-modified organopolysiloxane, dimethylsiloxane·methylcetyloxysiloxane copolymer, dimethylsiloxane·methylstearoxysiloxane copolymer, alkyl-modified organopolysiloxane, end-modified organopolysiloxane, amino-modified silicone oil, amino-modified organopolysiloxane, dimethiconol, silicone gel, acrylic silicone, trimethylsiloxysilicic acid, silicone RTV rubber, etc. Fluorine-based oil phase components: perfluoropolyether, fluorine-modified organopolysiloxane, fluorinated pitch, fluorocarbon, fluoroalcohol, fluoroalkyl·polyoxyalkylene copolymer-modified organopolysiloxane, etc.

[0025] (2) Examples of higher alcohols Lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, behenyl alcohol, 2-ethylhexanol, hexadecyl alcohol, octyldodecanol, etc.

[0026] (3) Examples of fatty acids Caprylic acid, capric acid, undecylenic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, arachidic acid, arachidonic acid, behenic acid, erucic acid, 2-ethylhexanoic acid, etc.

[0027] (4) Examples of ultraviolet absorbers Para - aminobenzoic acid, amyl para - aminobenzoate, ethyl dihydroxypropyl para - aminobenzoate, glyceryl para - aminobenzoate, ethyl para - aminobenzoate, octyl para - aminobenzoate, octyldimethyl para - aminobenzoate, ethylene glycol salicylate, octyl salicylate, triethanolamine salicylate, phenyl salicylate, butylphenyl salicylate, benzyl salicylate, homomenthyl salicylate, benzyl cinnamate, octyl paramethoxycinnamate, 2 - ethylhexyl paramethoxycinnamate, glyceryl mono - 2 - ethylhexanoate diparamethoxycinnamate, isopropyl paramethoxycinnamate, diethanolamine salt of paramethoxyhydroxycinnamic acid, diisopropyl · diisopropyl cinnamate ester mixture, urocanic acid, ethyl urocanic acid, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and its salts, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxybenzophenone, dihydroxydimethoxybenzophenone, hydroxyoctoxybenzophenone, tetrahydroxybenzophenone, butylmethoxydibenzoylmethane, 2,4,6 - trianilino - p - (carbo - 2 - ethylhexyl - 1 - oxy) - 1,3,5 - triazine, 2 - (2 - hydroxy - 5 - methylphenyl) benzotriazole, methyl - O - aminobenzoate, 2 - ethylhexyl - 2 - cyano - 3,3 - diphenylacrylate, phenylbenzimidazole sulfonic acid, 3 - (4 - methylbenzylidene) camphor, isopropyldibenzoylmethane, 2 - ethylhexyl 4 - (3,4 - dimethoxyphenylmethylene) - 2,5 - dioxo - 1 - imidazolidinepropionate, and the like, and their polymer derivatives, silane derivatives, etc.

[0028] (5) Examples of powders and pigments Dyes such as Red No. 104, Red No. 201, Yellow No. 4, Blue No. 1, Black No. 401, Lake pigments such as Yellow No. 4 AL Lake, Yellow No. 203 BA Lake, Nylon powder, Silk powder, Urethane powder, Teflon (registered trademark) powder, Silicon powder, Methyl polymethacrylate powder, Cellulose powder, Starch, Silicon elastomer spherical powder, Polymers such as polyethylene powder, Colored pigments such as Yellow iron oxide, Red iron oxide, Black iron oxide, Chromium oxide, Carbon black, Ultramarine, Cobalt blue, White pigments such as Zinc oxide, Titanium oxide, Cerium oxide, Extender pigments such as Talc, Mica, Sericite, Kaolin, Plate-like barium sulfate, Pearl pigments such as Mica titanium, Metal salts such as Barium sulfate, Calcium carbonate, Magnesium carbonate, Aluminum silicate, Magnesium silicate, Inorganic powders such as Silica, Alumina, Metal soaps such as Aluminum stearate, Magnesium stearate, Zinc palmitate, Zinc myristate, Magnesium myristate, Zinc laurate, Zinc undecylenate, Bentonite, Smectite, Boron nitride, etc. There are no particular restrictions on the shape (spherical, rod-shaped, needle-shaped, plate-shaped, irregular shape, flaky, spindle-shaped, etc.) and particle size of these powders. These powders may or may not have been surface-treated in advance by conventionally known surface treatments such as fluorine compound treatment, silicone treatment, silicone resin treatment, pendant treatment, silane coupling agent treatment, titanium coupling agent treatment, oil treatment, N-acylation lysine treatment, polyacrylic acid treatment, metal soap treatment, amino acid treatment, lecithin treatment, inorganic compound treatment, plasma treatment, mechanochemical treatment, etc.

[0029] (6) Examples of surfactants Anionic surfactants: fatty acid soaps, α-acyl sulfonates, alkyl sulfonates, alkyl allyl sulfonates, alkyl naphthalene sulfonates, alkyl sulfates, POE alkyl ether sulfates, alkyl amide sulfates, alkyl phosphates, POE alkyl phosphates, alkyl amide phosphates, alkyloyl alkyl taurates, N-acyl amino acid salts, POE alkyl ether carboxylates, alkyl sulfosuccinates, sodium alkyl sulfoacetates, acylated hydrolyzed collagen peptide salts, perfluoroalkyl phosphate esters, etc. Cationic surfactants: alkyl trimethyl ammonium chlorides, stearyl trimethyl ammonium chlorides, stearyl trimethyl ammonium bromides, cetostearyl trimethyl ammonium chlorides, distearyl dimethyl ammonium chlorides, stearyl dimethyl benzyl ammonium chlorides, behenyl trimethyl ammonium bromides, benzalkonium chlorides, behenic acid amide propyl dimethyl hydroxypropyl ammonium chlorides, stearic acid diethylaminoethyl amides, stearic acid dimethylaminopropyl amides, lanolin derivative quaternary ammonium salts, etc. Amphoteric surfactants: carboxy betaine type, amide betaine type, sulfo betaine type, hydroxy sulfo betaine type, amide sulfo betaine type, phospho betaine type, amino carboxylate type, imidazoline derivative type, amide amine type, etc. Nonionic surfactants: propylene glycol fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, POE sorbitan fatty acid esters, POE sorbit fatty acid esters, POE glycerin fatty acid esters, POE alkyl ethers, POE fatty acid esters, POE hydrogenated castor oil, POE castor oil, POE·POP copolymers, POE·POP alkyl ethers, polyether-modified silicone lauric acid alkanolamides, alkyl amine oxides, hydrogenated soybean phospholipids, etc. Natural surfactants: lecithin, saponin, sugar-based surfactants, etc.

[0030] (7) Examples of polyhydric alcohols and sugars Ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, glycerin, diglycerin, polyglycerin, 3-methyl-1,3-butanediol, 1,3-butylene glycol, sorbitol, mannitol, raffinose, erythritol, glucose, sucrose, fructose, xylitol, lactose, maltose, maltitol, trehalose, alkylated trehalose, mixed isomerized sugar, sulfated trehalose, pullulan, etc. are mentioned. Further, chemical modified products thereof and the like can also be used.

[0031] (8) Examples of polymers Acrylic acid ester / methacrylic acid ester copolymer (plus size, manufactured by Gohsei Chemical Co., Ltd.), vinyl acetate / crotonic acid copolymer (Resin 28-1310, manufactured by NSC), vinyl acetate / crotonic acid / vinyl neodecanoate copolymer (28-2930, manufactured by NSC), methyl vinyl ether maleic acid half ester (Gantrez ES, manufactured by ISP), t-butyl acrylate / ethyl acrylate / methacrylic acid copolymer (Lubimer, manufactured by BASF), vinyl pyrrolidone / vinyl acetate / vinyl propionate copolymer (Lubrisol VAP, manufactured by BASF), vinyl acetate / crotonic acid copolymer (Lubset CA, manufactured by BASF), vinyl acetate / crotonic acid / vinyl pyrrolidone copolymer (Lubset CAP, manufactured by BASF), vinyl pyrrolidone / acrylate copolymer (Lubiflex, manufactured by BASF), acrylate / acrylamide copolymer (Ultrahold, manufactured by BASF), vinyl acetate / butyl maleate / isobornyl acrylate copolymer (Advantage, manufactured by ISP), anionic polymer compounds such as carboxyvinyl polymer (Carbopol, manufactured by BFGoodrich), acrylic acid / methacrylic acid alkyl copolymer (Pemulen, manufactured by BF Goodrich), etc., amphoteric polymer compounds such as amphoteric acetate of dialkylaminoethyl methacrylate polymer (Yukafolmer, manufactured by Mitsubishi Chemical), octyl acrylamide / acrylic acid / hydroxypropyl methacrylate / butylaminoethyl methacrylate copolymer (Amphomer, manufactured by NSC), etc., cationic polymer compounds such as quaternized product of vinyl pyrrolidone / dimethylaminoethyl methacrylate (GAFQUAT, manufactured by ISP), methyl vinyl imidazolium chloride / vinyl pyrrolidone copolymer (Lubricote, manufactured by BASF), etc., nonionic polymer compounds such as polyvinyl pyrrolidone (Lubrisol K, manufactured by BASF), vinyl pyrrolidone / vinyl acetate copolymer (Lubrisol VA, manufactured by BASF), vinyl pyrrolidone / dimethylaminoethyl methacrylate copolymer (Copolymer 937, manufactured by ISP), vinyl caprolactam / vinyl pyrrolidone / dimethylaminoethyl methacrylate copolymer (Copolymer VC713, manufactured by ISP), etc.In addition, naturally derived polymer compounds such as cellulose or its derivatives, keratin, collagen or its derivatives, calcium alginate, pullulan, agar, gelatin, tamarind seed polysaccharide, xanthan gum, carrageenan, high methoxyl pectin, low methoxyl pectin, guar gum, gum arabic, crystalline cellulose, arabinogalactan, karaya gum, tragacanth gum, alginic acid, albumin, casein, curdlan, gellan gum, dextran, etc. can also be preferably used.

[0032] (9) Examples of bioactive ingredients Examples of physiologically active ingredients include substances that impart some physiological activity to the skin when applied thereto. For example, whitening agents, immunostimulants, anti-aging agents, ultraviolet protectants, slimming agents, tightening agents, antioxidants, hair growth stimulants, hair tonics, moisturizers, blood circulation promoters, antibacterial agents, germicides, desiccants, cooling agents, warming agents, vitamins, amino acids, wound healing promoters, irritation relievers, analgesics, cell activators, enzyme components, and the like. Examples of these preferred compounding ingredients include, for example, ashitaba extract, avocado extract, amacha extract, hollyhock extract, arnica extract, aloe extract, apricot extract, apricot kernel extract, ginkgo extract, morning glory extract, turmeric extract, oolong tea extract, ginseng extract, etinashi leaf extract, saffron extract, peony extract, turmeric extract, barley extract, chickweed extract, odoratum extract, horseradish extract, orange extract, dried seawater, seaweed extract, hydrolyzed elastin, hydrolyzed wheat flour, hydrolyzed silk, chamomile extract, carrot extract, mugwort extract, licorice extract, calcarea extract, kakyo extract, cinchona extract, cucumber extract, guanosine, gardenia extract, kumazasa extract, clara extract, walnut extract, grapefruit extract, clematis extract, chlorella extract, mulberry extract, gentiana extract, black tea extract, yeast extract, burdock extract, rice bran fermented extract, rice germ oil, comfrey extract, collagen, loquat extract, saikosaponin extract, psycotria extract, saitoa extract, sage extract, soapwort extract, sasaki extract, Japanese medlar extract, sansho extract, shiitake extract, angelica extract, shikon extract, perilla extract, cinnamon extract, cimicifuga extract, Chinese peony extract, arrowroot rhizome extract, silver birch extract, sweet violet extract, common ivy extract, European medlar extract, European chickweed extract, peppermint extract, sage extract, Japanese butterbur extract, senkyu extract, centella extract, soybean extract, thallus extract, thyme extract, tea extract, clove extract, chigaya extract, chinpi extract, toki extract, tokyo aster extract, toonin extract, thuja extract, dokudami extract, tomato extract, natto extract, carrot extract, garlic extract, rose extract, hibiscus extract,Examples include Bacopa monnieri extract, parsley extract, honey, witch hazel extract, Parietaria diffusa extract, Coix lacryma-jobi extract, bisabolol, loquat extract, Flos farfarae extract, Petasites japonicus extract, Buchloe dactyloides extract, Butcher's broom extract, grape extract, propolis, Luffa cylindrica extract, Carthamus tinctorius extract, peppermint extract, Ficus carica extract, button extract, hops extract, pine extract, plane tree extract, Zingiber mioga extract, Diospyros kaki extract, Melissa officinalis extract, peach extract, Crepis crocea extract, eucalyptus extract, Saxifraga stolonifera extract, Polygonatum odoratum extract, mugwort extract, lavender extract, apple extract, lettuce extract, lemon extract, Lactuca indica extract, rose extract, rosemary extract, Roman chamomile extract, royal jelly extract, etc. In addition, biopolymers such as deoxyribonucleic acid, mucopolysaccharides, sodium hyaluronate, sodium chondroitin sulfate, collagen, elastin, chitin, chitosan, hydrolyzed eggshell membrane, moisturizing components such as amino acids, hydrolyzed peptides, sodium lactate, urea, sodium pyrrolidone carboxylate, betaine, whey, trimethylglycine, oily components such as sphingolipids, ceramides, phytosphingosine, cholesterol, cholesterol derivatives, phospholipids, immunostimulants such as ε-aminocaproic acid, glycyrrhizic acid, β-glycyrrhetinic acid, lysozyme chloride, guaiazulene, hydrocortisone, vitamins such as vitamin A, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, calcium pantothenate, biotin, nicotinamide, vitamin C ester, active ingredients such as allantoin, diisopropylamine dichloroacetate, 4-aminomethylcyclohexanecarboxylic acid, antioxidants such as tocopherol, carotenoid, flavonoid, tannin, lignan, saponin, cell activators such as α-hydroxy acid, β-hydroxy acid, blood circulation promoters such as γ-oryzanol, vitamin E derivatives, wound healers such as retinol, retinol derivatives, skin lightening agents such as arbutin, kojic acid, placenta extract, sulfur, ellagic acid, linoleic acid, tranexamic acid, glutathione, cephalanthin, licorice extract, capsicum tincture, hinokitiol, garlic iodide extract, pyridoxine hydrochloride, DL-α-tocopherol, DL-α-tocopherol acetate, nicotinic acid, nicotinic acid derivatives, calcium pantothenate, D-pantothenyl alcohol, acetylpantothenyl ethyl ether, biotin, allantoin, isopropylmethylphenol, estradiol, ethinyl estradiol, capronium chloride, benzalkonium chloride, diphenhydramine hydrochloride, takanal, camphor, salicylic acid, nonyl vanillylamide, nonanoic acid vanillylamide, piroctone olamine, glyceryl pentadecanoate, L-menthol, mononitroguaiacol, resorcinol, γ-aminobutyric acid, benzethonium chloride, mexiletine hydrochloride, auxin, female hormones, cantharis tincture, cyclosporine, zinc pyrithione, hydrocortisone, minoxidil, polyoxyethylene sorbitan monostearate, peppermint oil,Examples include hair tonics containing Sasa nishiki extract and the like.

[0033] (10) Examples of antioxidants Examples include sodium bisulfite, sodium sulfite, erythorbic acid, sodium erythorbate, dilauryl thiodipropionate, tocopherol, trylbiguanide, nordihydroguaiaretic acid, para - hydroxyanisole, butylhydroxyanisole, dibutylhydroxytoluene, ascorbyl stearate, ascorbyl palmitate, octyl gallate, propyl gallate, carotenoid, flavonoid, tannin, lignan, saponin, and plant extracts such as apple extract and clove extract that have antioxidant effects.

[0034] (11) Examples of solvents Examples include purified water, ethanol, lower alcohols, ethers, LPG, fluorocarbons, N - methylpyrrolidone, fluoroalcohols, volatile linear silicones, and next - generation chlorofluorocarbons.

[0035] The transdermal water loss inhibitor of the present invention can be used as a raw material for food and beverage compositions, pharmaceutical compositions, and topical skin preparations. As formulation raw materials that can be blended therein, those similar to those used for the above - mentioned transdermal water loss inhibitor can be used, and the manufacturing method and administration method can also be the same as those of the transdermal water loss inhibitor.

Examples

[0036] Hereinafter, examples of the present invention will be described. Note that the examples shown below are for confirming various actions and effects of the transdermal water loss inhibitor obtained by the present invention, and the scope of the present invention is not limited to these products and manufacturing methods.

[0037] Example (1) Isolation of "Kuzu no Tsuru lactic acid bacteria" "Kuzu no Tsuru lactic acid bacteria" belonging to Leuconostoc mesenteroides was isolated by the following procedure. · Cultivate the vine of kudzu in a liquid medium for lactic acid bacteria supplemented with antibiotics at 25°C to 37°C for 24 to 48 hours by accumulation culture. The obtained culture solution was spread and cultured on a BCP-added plate count agar medium, and 5 new strains of vine belonging to Leuconostoc mesenteroides were selected. The "Kudzu Vine Lactic Acid Bacteria" belonging to Leuconostoc mesenteroides obtained as described above was deposited on July 11, 2018, at the Patent Biological Deposit Center (NITE-IPOD), Biotechnology Center, National Institute of Technology and Evaluation (Deposit number NITE P-02751). (2) 16S rDNA gene analysis of "Kudzu Vine Lactic Acid Bacteria" The nucleotide sequence of the 16S rDNA gene of the isolated "Kudzu Vine Lactic Acid Bacteria" was determined. The results are shown in Figure 8 (SEQ ID NO: 1). Figure 9 is an alignment comparing the 16S rDNA gene of the "Kudzu Vine Lactic Acid Bacteria" strain (SIID23149-01 in the upper row, SEQ ID NO: 1) with the RIB.9186 strain belonging to Leuconostoc mesenteroides as the comparison target (obtained from the National Research Institute of Brewing, SIID23149-02 in the lower row, SEQ ID NO: 2). Figure 10 is a simple molecular phylogenetic tree based on the nucleic acid sequence of the 16S rDNA gene of "Kudzu Vine Lactic Acid Bacteria". The line at the upper left is the scale bar, the numerical values located at the branches of the phylogenetic tree are bootstrap values, and the "T" at the end of the strain name indicates the type strain of that species.

[0038] Test Example 1: Evaluation of the Transepidermal Water Loss (TEWL) of "Kudzu Vine Lactic Acid Bacteria" Test method Hairless mice were orally administered with the powder of "Kuzunotsuru lactic acid bacteria" (Deposit number at the Patent Microorganisms Depositary: NITE NITE P-02751) (50 or 100 mg / kg) for 28 days, and the TEWL of the back skin was measured. Then, an aqueous solution of sodium dodecyl sulfate (SDS solution) was applied to the right side across the midline for 5 minutes and wiped. This operation was repeated for 3 days, and the next day, the TEWL was measured again. Further, the skin was collected the day after that, and the mRNA expression levels of involucrin, filaggrin, and transglutaminase 1 were examined. The results are shown in Fig. 1 (before SDS application), Fig. 2 (after SDS application), Fig. 3 (change amount before and after SDS application), and Fig. 4 (difference between the applied site and non-applied site after SDS application). Fig. 5 shows the expression level of involucrin, Fig. 6 shows the expression level of filaggrin, and Fig. 7 shows the expression level of transglutaminase 1. These are proteins present in the cornified envelope of the stratum corneum. Involucrin is involved in the keratinization of epidermal cells, filaggrin binds to keratin to strengthen the stratum corneum, and transglutaminase 1 promotes the cross-linking of keratin proteins.

[0039] Measurement results and effects of the examples in Test Example 1 As shown in Figs. 1 and 2, it was confirmed that the TEWL was suppressed by "Kuzunotsuru lactic acid bacteria" by administration, and particularly, the TEWL was suppressed at the SDS application site. Also, as shown in Fig. 3, it was confirmed that the inhibitory effect on TEWL had an excellent concentration-dependent effect at the SDS application site. Further, as shown in Fig. 4, when examining the difference between the SDS applied part and the non-applied part, it can be seen that the TEWL decreased significantly compared to the control in the administration of 100 mg / kg. Furthermore, as shown in Figs. 5 and 7, the expression levels of involucrin and transglutaminase 1 increased significantly, and the expression level of filaggrin also showed an increasing trend as shown in Fig. 6. Therefore, "Kuzunotsuru lactic acid bacteria" is considered to increase the expression levels of stratum corneum proteins involved in moisturizing and barrier functions. As described above, "Kuzunotsuru lactic acid bacteria" is useful as a TEWL inhibitor, and thereby it has been confirmed to be useful as a moisturizing agent. In addition, since it particularly inhibits TEWL at the SDS application site, it has been confirmed to be useful also as a skin roughness improver.

[0040] Test Example 2: Clinical trial of "Kuzunotsuru lactic acid bacteria" 1. Test outline · Test period: May 14 - June 25 (6 weeks) · Subjects: 27 persons (20 males, 8 females) · Test design: Double - blind comparative test (placebo group: 14 persons, lactic acid bacteria group: 14 persons) One female in the placebo group dropped out due to poor physical condition. · Test method: Conducted by measuring salivary IgA, dermal collagen density, TEWL (trans - epidermal water loss), and questionnaire (questionnaire regarding skin quality). The above - mentioned dermal collagen density was measured by using Dermarabo (registered trademark) to measure the collagen score (in Dermarabo, it represents the density of collagen in the dermis. Generally, the larger the value, the richer the collagen and the better the state of dermal collagen). ※ The questionnaire was created referring to "Effects of taking lactic acid bacteria - fermented filtrate PS - B1 on defecation, stool properties, and skin quality" published in the Journal of the Japanese Society for Food Science and Nutrition, Vol. 30, No. 3, pp. 112 - 122 (2020), and the subjects were asked to answer the form shown in Table 1 below. The results are shown in Figure 11 (TEWL (cheek)), Figure 12 (TEWL (arm)), Figure 13 (salivary IgA), Figure 14 (change amount of Dermarabo (collagen score)), and Table 2 (skin quality questionnaire).

Table 1

[0041]

Table 2

[0042] Results and effects of the examples in Test Example 2 (1) Trans - epidermal water loss (TEWL) (cheek) As shown in Fig. 11, both the placebo group and the lactic acid bacteria intake group showed a significant decrease at 4 weeks (4W) and 6 weeks (6W) of intake within each group compared to before intake (0W). Although there was no significant difference between the groups, an improving trend was observed in the lactic acid bacteria intake group. As a result, it was confirmed that "Kuzunotsuru lactic acid bacteria" has an effect of improving TEWL on the cheeks. (2) Trans-epidermal water loss (TEWL) (arm) As shown in Fig. 12, both the placebo group and the lactic acid bacteria intake group showed a significant decrease at 4W and 6W of intake within each group compared to before intake (0W). Although there was no significant difference between the groups, an improving trend was observed in the lactic acid bacteria intake group. As a result, it was confirmed that "Kuzunotsuru lactic acid bacteria" also has an effect of improving TEWL on the arm. (3) Salivary IgA As shown in Fig. 13, only in the lactic acid bacteria intake group, the amount of IgA increased significantly at 4W compared to before intake (0W). Although there was no significant difference between the groups, an increasing trend of IgA was observed in the lactic acid bacteria intake group (see Fig. 13). As a result, it was confirmed that "Kuzunotsuru lactic acid bacteria" has an effect of increasing IgA. (4) Dermalab (dermal collagen density) As shown in Fig. 14, the collagen score, which is an index indicating the density of dermal collagen, increased significantly at both 4W and 6W in the lactic acid bacteria intake group only compared to before intake (0W). Also, although there was no significant difference between the groups, an increasing trend was observed in the lactic acid bacteria intake group. As a result, it was confirmed that "Kuzunotsuru lactic acid bacteria" has an effect of improving the density of dermal collagen.

[0043] (5) Questionnaire (skin quality related) As shown in Table 2, in the item of "shiny skin", there was a significant improvement at 4W in the lactic acid bacteria intake group only compared to before intake (0W), and there was also an improving trend at 6W. Also, in the item of "firm skin", there was a significant improvement at 6W in the lactic acid bacteria intake group only compared to before intake (0W). Also, in the item of "even - colored skin", there was an improving trend at 4W in the lactic acid bacteria intake group only compared to before intake (0W). Furthermore, in the item of "skin not bothered by stickiness", there was no significant difference in the lactic acid bacteria intake group, but while the placebo deteriorated, there was no change in the lactic acid bacteria intake group. Therefore, it can be said that there was a tendency for improvement when compared with the placebo. Also, in the item of "skin not bothered by dryness", only the lactic acid bacteria intake group showed significant improvement at 4W and 6W compared to before intake (0W). From this result, it was confirmed that Kudzu-vine lactic acid bacteria have an effect of improving skin quality.

[0044] From the above results, in addition to the effects of improving trans-epidermal water loss (TEWL) and collagen density, and the effect of increasing salivary IgA, it was confirmed from the questionnaire (related to skin quality) that 'Kudzu-vine lactic acid bacteria' has a W-barrier function for the skin and immunity.

[0045] Formulation examples of the trans-epidermal water loss inhibitor ('Kudzu-vine lactic acid bacteria') according to the present invention are shown. Note that the following formulation examples do not limit the present invention. Formulation Example 1: Chewing gum Sugar 53.0 wt% Gum base 20.0 Glucose 10.0 Maltose 16.0 Flavor 0.5 Transdermal water loss inhibitor 0.5 100.0 wt%

[0046] Formulation Example 2: Gummy Reduced maltose 40.0 wt% Granulated sugar 20.0 Fructose 20.0 Gelatin 4.7 Water 9.68 Yuzu juice 4.0 Yuzu flavor 0.6 Dye 0.02 Transdermal water loss inhibitor 1.0 100.0 wt%

[0047] Formulation Example 3: Candy Sugar 50.0 wt% Maltose 33.0 Water 14.4 Organic acid 2.0 Fragrance 0.2 Transdermal water loss inhibitor 0.4 100.0 wt%

[0048] Formulation Example 4: Yogurt (hard - soft) Milk 41.5 wt% Skim milk powder 5.8 Sugar 8.0 Agar 0.15 Gelatin 0.1 Lactic acid bacteria 0.005 Transdermal water loss inhibitor 0.4 Fragrance Trace amount Water residue 100.0 wt%

[0049] Formulation Example 5: Soft drink Fructose - glucose liquid sugar 30.0 wt% Emulsifier 0.5 Transdermal water loss inhibitor 0.3 Fragrance Appropriate amount Purified water residue 100.0 wt%

[0050] Formulation Example 6: Tablet confectionery Sugar 76.4 wt% Glucose 19.0 Sucrose fatty acid ester 0.2 Transdermal water loss inhibitor 0.5 Purified water 3.9 100.0 wt%

[0051] Formulation Example 7: Soft capsule Brown rice germ oil 47.0 wt% Yuzu seed oil 40.0 Emulsifier 12.0 Transdermal water loss inhibitor 1.0 100.0 wt%

[0052] Formulation Example 8: Tablet Lactose 54.0 wt% Crystalline cellulose 30.0 Starch degradation product 10.0 Glycerin fatty acid ester 5.0 Transdermal water loss inhibitor 1.0 100.0 wt%

[0053] Formulation Example 9: Makeup cream Squalane 20.0 wt% Beeswax 5.0 Refined jojoba oil 5.0 Glycerin 5.0 Glycerin monostearate 2.0 Polyoxyethylene (20) sorbitan - Monostearate 2.0 Transdermal water loss inhibitor 2.0 Preservative Appropriate amount Fragrance Appropriate amount Purified water residue 100.0 wt%

[0054] Formulation Example 10: Lotion Ethanol 5.0 wt% Glycerin 2.0 1,3 - Butylene glycol 2.0 Polyethylene oleyl ether 0.5 Sodium citrate 0.1 Citric acid 0.1 Transdermal water loss inhibitor 0.1 Purified water residue 100.0 wt%

[0055] Formulation Example 11: Body gel Macadamia nut oil 2.0 wt% Octyldodecyl myristate 10.0 Methylphenylpolysiloxane 5.0 Behenyl alcohol 3.0 Stearic acid 3.0 Batyl alcohol 1.0 Glyceryl monostearate 1.0 Polyoxyethylene sorbitol tetraoleate 2.0 Hydrogenated soy phospholipid 1.0 Ceramide 0.1 Retinol palmitate 0.1 Preservative Appropriate amount Tsubokusa extract 1.0 Transdermal water loss inhibitor 1.0 1,3-Butylene glycol 5.0 Purified water residue 100.0 wt%

[0056] Formulation Example 12: Emulsion Squalane 4.0 wt% Petrolatum 2.5 Cetanol 2.0 Glycerin 2.0 Lipophilic glycerol monostearate 1.0 Stearic acid 1.0 L-Arginine 1.0 Transdermal water loss inhibitor 0.5 Potassium hydroxide 0.1 Fragrance Trace amount Purified water residue 100.0 wt%

[0057] Formulation Example 13: Bath agent (liquid) Propylene glycol 50.0 wt% Ethanol 20.0 Sodium sulfate 5.0 Transdermal water loss inhibitor 0.5 Lanolin 0.5 Avocado oil 0.5 Dye 1.5 Fragrance 22.0 100.0 wt%

Industrial Applicability

[0058] As described above, the present invention can provide a novel transdermal water loss inhibitor.

Deposit Number

[0059] The "Tsurugi 5" strain belonging to Leuconostoc mesenteroides was deposited on July 11, 2018, at the Patent Microorganisms Depositary, Biotechnology Center, National Institute of Technology and Evaluation (NITE-IPOD) (Accession No. NITE P-02751).

Sequence Listing Free-Text

[0060] SEQ ID NO: 1: Nucleotide sequence of the 16S rDNA gene of the "Tsurugi 5" strain SEQ ID NO: 2: Nucleotide sequence of the 16S rDNA gene of the RIB.9186 strain belonging to Leuconostoc mesenteroides

Claims

1. A filaggrin expression promoter comprising, as an active ingredient, a lactic acid bacterium (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751).

2. An involucrin expression promoter containing, as an active ingredient, a lactic acid bacterium (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751).

3. A transglutaminase 1 expression promoter comprising, as an active ingredient, a lactic acid bacterium (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751).

4. An oral dermal collagen density improving agent containing, as an active ingredient, a lactic acid bacterium (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751).

5. A salivary IgA increaser containing as an active ingredient a lactic acid bacterium (Leuconostoc mesenteroides) strain derived from kudzu vines (Patent Microorganisms Deposit Center Accession Number: NITE P-02751).

Images